The Manufacturers Life Insurance Company Has $73,000 Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

The Manufacturers Life Insurance Company boosted its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 87.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 24,524 shares of the company’s stock after acquiring an additional 11,450 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Trevi Therapeutics were worth $73,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in TRVI. Logos Global Management LP lifted its position in shares of Trevi Therapeutics by 27.3% during the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock worth $8,344,000 after purchasing an additional 600,000 shares in the last quarter. Ally Bridge Group NY LLC bought a new position in Trevi Therapeutics in the 2nd quarter worth approximately $4,395,000. Hsbc Holdings PLC acquired a new position in Trevi Therapeutics during the 2nd quarter worth $61,000. Dimensional Fund Advisors LP boosted its position in Trevi Therapeutics by 217.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 72,210 shares of the company’s stock valued at $215,000 after buying an additional 49,475 shares during the last quarter. Finally, American Century Companies Inc. boosted its position in Trevi Therapeutics by 17.1% in the 2nd quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock valued at $161,000 after buying an additional 7,902 shares during the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Analyst Ratings Changes

TRVI has been the topic of several research reports. HC Wainwright started coverage on Trevi Therapeutics in a research note on Friday, August 30th. They set a “buy” rating and a $6.00 price target on the stock. Raymond James began coverage on shares of Trevi Therapeutics in a research report on Friday, August 30th. They set an “outperform” rating and a $9.00 target price on the stock. Leerink Partners began coverage on shares of Trevi Therapeutics in a research note on Monday, September 9th. They issued an “outperform” rating and a $7.00 target price on the stock. B. Riley reissued a “buy” rating and set a $6.00 price target on shares of Trevi Therapeutics in a research note on Monday, October 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a research note on Friday, October 4th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $7.43.

Trevi Therapeutics Price Performance

Shares of NASDAQ:TRVI opened at $3.12 on Monday. The firm’s 50 day simple moving average is $3.08 and its 200 day simple moving average is $2.89. Trevi Therapeutics, Inc. has a fifty-two week low of $0.97 and a fifty-two week high of $4.00. The company has a market capitalization of $226.48 million, a price-to-earnings ratio of -8.00 and a beta of 0.97.

Trevi Therapeutics (NASDAQ:TRVI) last posted its earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same period in the prior year, the business posted ($0.07) EPS. Equities research analysts expect that Trevi Therapeutics, Inc. will post -0.47 earnings per share for the current year.

Insider Buying and Selling

In other Trevi Therapeutics news, CEO Jennifer L. Good sold 10,981 shares of Trevi Therapeutics stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total transaction of $33,162.62. Following the transaction, the chief executive officer now directly owns 213,313 shares in the company, valued at approximately $644,205.26. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Trevi Therapeutics news, CEO Jennifer L. Good sold 10,981 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the sale, the chief executive officer now directly owns 213,313 shares in the company, valued at approximately $644,205.26. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Thomas Sciascia sold 18,660 shares of Trevi Therapeutics stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $2.76, for a total transaction of $51,501.60. Following the completion of the transaction, the insider now directly owns 220,315 shares in the company, valued at approximately $608,069.40. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 40,355 shares of company stock valued at $116,663. 24.37% of the stock is owned by company insiders.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.